There are currently 1253 clinical trials in Columbus, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Nationwide Children's Hospital, Ohio State University Comprehensive Cancer Center, Ohio State University and The Ohio State University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
NCT05798663
Recruiting
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Ohio State University, Columbus, Ohio
Conditions: NSCLC
Register for Updates
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
NCT05624918
Recruiting
This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8 and 15), and TTFields (worn every day for at least 18 hours). Following the initial 3 cycles of gemcitabine/nab-paclitaxel/TTFields treatment, patients will undergo restaging by CT or MRI. Patients with stable disease or better will undergo surgery for resection within 8 weeks following completion of initial chemotherapy although enrolling sites ar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Pancreatic Adenocarcinoma, Resectable Pancreatic Cancer
Register for Updates
Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors
NCT05452681
Recruiting
The purpose of this two-arm pilot RCT is to evaluate processes and preliminary outcomes of a targeted QOL intervention vs. an attention control among young AA survivors post-treatment for early (I-II) \& late (III) stage breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
07/29/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Breast Cancer, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Register for Updates
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
NCT05835466
Recruiting
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study per... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Register for Updates
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202
Recruiting
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Optimed Research Ltd - ClinEdge - PPDS, Columbus, Ohio
Conditions: Chronic Spontaneous Urticaria
Register for Updates
Post Market Evaluation of Clinical Safety and Performance of the Fitbone Transport and Lengthening System
NCT06400732
Recruiting
This is an open-label, prospective, observational, post-market, uncontrolled, multi-center study intended to evaluate the safety and clinical performance of the FITBONE Transport and Lengthening Nail when used according to the manufacturer's Instructions for Use. The FITBONE Transport \& Lengthening Nail is a variant of the FITBONE TAA Nail, which has been commercially available in the US since 2017. The clinical performance and safety of the medical device have been assessed based on mechanical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Fractures, Bone, Fractures, Closed, Fractures, Open, Fracture of Femur, Fracture Nonunion, Fracture of Tibia, Limb Deformity, Limb Fracture, Limb Defect, Limb Asymmetry
Register for Updates
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/29/2025
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio +1 locations
Conditions: Parkinson Disease
Register for Updates
Registry for Stage 2 Type 1 Diabetes
NCT06481904
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Columbus Regional Healthcare- Site Number : 8400013, Columbus, Ohio +1 locations
Conditions: Type 1 Diabetes
Register for Updates
Study of SGR-3515 In Participants With Advanced Solid Tumors.
NCT06463340
Recruiting
The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Ohio State University, Columbus, Ohio
Conditions: Advanced Solid Tumor
Register for Updates
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
NCT06891755
Recruiting
The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATHE Airway Scaffold is a permanent implant designed to tent open native airways. The study will include up to 250 participants at up to 25 study centers located in the United States and Europe. Study su... Read More
Gender:
ALL
Ages:
Between 40 years and 84 years
Trial Updated:
07/29/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: COPD, Emphysema
Register for Updates
Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds
NCT06787690
Recruiting
The goal of this study is to look at clinical outcomes when Cohealyx Collagen Matrix is used to treat full thickness wounds after surgical excision in patients that require a skin graft to heal their wounds. The main question it aims to answer is how long does it take for Cohealyx to support definitive closure.
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Ohio State University, Columbus, Ohio
Conditions: Burn, Trauma Wound, Full Thickness Wounds, Surgical Wound
Register for Updates
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT06930625
Recruiting
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Acromegaly
Register for Updates